T1	Participants 325 375	previously treated patients with advanced melanoma
T2	Participants 529 695	nrollment in the phase III trial was restricted to class-I HLA-A*0201-positive patients because two of the three arms contained an HLA-A*0201-restricted gp100 vaccine
